According to a recent LinkedIn post from Okami Medical, a clinician used a single LOBO-9 device to occlude a 7.7 mm collateral vessel during endovascular repair of an iliac artery aneurysm. The procedure was performed via a 6 Fr Ansel sheath, with successful occlusion confirmed on angiography.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights a real-world case suggesting that Okami Medical’s LOBO occlusion technology can be deployed efficiently in complex vascular procedures. For investors, such clinical use cases may indicate growing physician adoption, potentially supporting future revenue growth and strengthening the company’s position in the endovascular embolization and vascular occlusion market.
The reference to additional published cases may point to a strategy of building an evidence base around the LOBO platform, which could be important for reimbursement discussions and broader market acceptance. While the post is promotional in nature, it underscores the company’s focus on demonstrating procedural efficiency and device performance in aneurysm repair workflows.